Press Releases Callewaert group
Helena Biosciences to develop automated blood test for chronic liver disease based on VIB and Ghent University research – 16 May 2017
Helena Biosciences announced today that it is commercialising a new blood test for Chronic Liver Disease (CLD) in cooperation with the Ghent University branch of VIB – the life sciences research institute of Flanders, Belgium. The Glyco Liver Profile will provide healthcare professionals with a comprehensive tool to diagnose and monitor patients with hepatic inflammation, fibrosis and cirrhosis, and identify cirrhosis patients at low and high risk of developing HCC within the years following the test.
Technology: the tools and methods to observe and to intervene in Nature – 9 July 2016
In molecular life sciences, the incredible ingenuity of scientists and engineers such as those at VIB leads to increasingly accurate analytical methods. These are used to study the structure of the molecules that make up living matter, and to elucidate how these molecules interact in the self-propagating far-from-equilibrium steady state that essentially constitutes Life. Importantly, these methods are also those used to detect the molecular alterations that occur in diseases of plants, humans and other animals, and are the basis for the diagnostics that will progressively change medicine (and agriculture) as we know it.
Turning plant seeds into medicine factories – 29 April 2016
Thanks to a collaboration between two VIB/UGent research groups, Ann Depicker and Nico Callewaert have achieved a biotechnology breakthrough. The GlycoDelete technology, which simplifies the production process for biotech medicines, was originally developed in mammalian cells by Nico Callewaert. By jointly applying this technology to plant seeds, the researchers have demonstrated that plant seeds can serve as a medium for the inexpensive and large-scale production of biotech medicines. The results of their research were published in Nature Biotechnology.
VIB/UGent researchers enable safer production of biotech medicines using plant seeds – 1 December 2015
The VIB and Ghent University professors Ann Depicker and Nico Callewaert have achieved a significant biotechnology breakthrough that targets the production of medicines. The GlycoDelete technology, which simplifies the production process for biotech medicines, was originally developed in mammalian cells by prof. Callewaert. By jointly applying this technology to plant seeds, the two researchers have demonstrated that plant seeds can also serve as a medium for the inexpensive large-scale production of biotech medicines. The results of their research were published in the leading scientific journal Nature Biotechnology.
Simple blood test measures risk of liver cancer – 27 October 2015
Researchers in Ghent have developed a test to measure the risk of liver cancer in people with cirrhosis of the liver. Their work will be revealed this week at United European Gastroenterology, the most important European conference for stomach, bowel and liver specialists.
Bypassing obstacles of reverse genetics research approaches – 30 September 2015
A fundamental method in genetic research is the generation of large collections (‘libraries’) of mutant cells or organisms, or cells containing sequence variants of a particular gene. Making such libraries is quite straightforward but characterizing the library is a whole different matter. Kristof Vandewalle and Nico Callewaert (VIB Medical Biotechnology Center, UGent) together with colleagues from VIB and Ghent University have described a method that reports both on the sequence variant as well as on the physical location of sequence-tagged biological entities in well-plate archived clone collections.